Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic

ABSTRACT: Proteomic

TISSUE(S): ['brain']

SUBMITTER: Ying Yu

PROVIDER: OEX00021177 | NODE | 2022-12-31

REPOSITORIES: NODE

ACCESS DATA

Json Xml

Similar Datasets

PDEEV proteomic

Project description:PDEEV proteomic

2022-01-14 | OEX00015730 | NODE

Secretome of Bone Marrow Stroma-Derived Neural Progenitor Cells: Proteomic Analysis

Project description:We found the bone marrow stromal-derived neural progenitor cells secretome have the neural protection effect. Proteomic analysis was performed nn order to analyze the protection factor in the secretome. Keywords: Neural protection, secretome

2008-10-18 | GSE13242 | GEO

Proteomic Comparison Of DSRCT, Normal Mesenteric Tissues and ES

Project description:Desmoplastic small round cell tumor (DSRCT) is an aggressive malignancy that occurs predominantly in young adult males and is characterized by abdominopelvic sarcomatosis exhibiting multi-lineage cellular nests of epithelial, muscular, mesenchymal, and neural differentiation admixed with desmoplastic stroma. Prior to the recognition of the disease as a distinct clinical entity, DSRCT was invariably misclassified as poorly differentiated atypical cancer of the testes, ovary, mesentery, or gastrointestinal tract, and the chemotherapies used for those malignancies elicited poor clinical response. As previously reported, a tectonic shift in the treatment of these patients occurred after researchers made two astute observations: 1) DSRCT microscopically resembles other small round “blue cell” sarcoma subtypes (e.g., ES, rhabdomyosarcoma, synovial sarcoma), and 2) DSRCT and ES have the same N-terminal EWSR1 fusion partner. Proteomic analysis using a reverse-phase protein lysate array (RPPA) was used to elucidate biomarkers that distinguish DSRCT from adjacent normal tissue and Ewing sarcoma. This proteomic analysis revealed novel proteins, such as the androgen receptor and Syk, that may be susceptible to drug targeting, as well as oncogenic pathways like Akt-PI3K that are highly expressed in DSRCT.

2020-12-31 | GSE108687 | GEO

Potato proteomic and phospho-proteomic responses to P. operculella

Project description:Potato proteomic herbivory responses

| PRJEB95833 | ENA

Identification of an effective early signaling signature during neo-vasculogenesis in vivo by ex vivo proteomic profiling

Project description:Therapeutic neo-vasculogenesis in vivo can be achieved by the co-transplantation of human endothelial colony-forming progenitor cells (ECFCs) with mesenchymal stem/progenitor cells (MSPCs).The underlying mechanism is not completely understood thus hampering the development of novel stem cell therapies.We hypothesized that proteomic profiling could be used to retrieve the in vivo signaling signature during the initial phase of human neo-vasculogenesis. ECFCs and MSPCs were therefore either transplanted alone or co-transplanted subcutaneously into immune deficient mice. Early cell signaling, occurring within the first 24 hours in vivo, was analyzed using antibody microarray proteomic profiling.Vessel formation and persistence were verified in parallel transplants for up to 24 weeks. Proteomic analysis revealed significant alteration of regulatory components including caspases, calcium/calmodulin-dependent protein kinase, DNA protein kinase,human ErbB2 receptor-tyrosine kinase as well as mitogen-activated protein kinases.Therapeutic candidate caspase-4 was selected from array results for targeting vascular network formation in vitro as well as modulating therapeutic vasculogenesis in vivo. As a proof-of-principle, caspase-4 and general caspase-blocking led to diminished endothelial network formation in vitro and significantly decreased vasculogenesis in vivo. Proteomic profiling ex vivo thus unraveled a signaling signature which can be targeted to modulate neo-vasculogenesis in vivo.

2013-04-09 | GSE45896 | GEO

Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial.

Project description:Serum Proteomic Analysis of patients with Hidradenitis Suppurativa treated with Fostamatinib

2023-08-10 | GSE240607 | GEO

Exploratory identification of candidate biomarkers and molecular contributors to paclitaxel-induced peripheral neuropathy in patients with breast cancer through proteomic analysis

Project description:Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant adverse effect of paclitaxel in patients with breast cancer. However, reliable biomarkers for early detection and monitoring of CIPN are lacking.Methods: We investigated neurofilament light chain (NfL) and galectin-3 as candidate biomarkers for CIPN, and performed proteomic analysis to identify novel molecular contributors in two cohorts of patients with breast cancer undergoing paclitaxel therapy. Blood samples were collected longitudinally to measure NfL and galectin-3 levels. Differentially expressed proteins associated with CIPN onset were identified by proteomics.Results: NfL levels significantly increased in patients with CIPN, from as early as 3 weeks after treatment initiation. NfL levels were markedly higher in patients with vs. without CIPN. There were no changes or between-group differences in galectin-3 levels. Proteomic analysis identified upregulation of alcohol dehydrogenase 4 (ADH4) and downregulation of vesicular overexpressed in cancer prosurvival protein 1 (VOPP1) in CIPN, implicating oxidative stress and disrupted mitochondrial dynamics in the pathogenesis of CIPN.Conclusion: NfL represents a candidate biomarker for early detection of CIPN, and we identified proteins potentially associated with the development of CIPN. Our findings provide further insights into the pathogenesis of CIPN. Integrating biomarkers and proteomics paves the way for precision medicine to manage chemotherapy-induced toxicities.

2026-06-16 | GSE315782 | GEO

Clinical Proteomic Tumor Analysis Consortium (CPTAC)

Project description:Clinical Proteomic Tumor Analysis Consortium (CPTAC)

| PRJNA371289 | ENA

Proteomic and phosphoproteomic data

Project description:Proteomic and phosphoproteomic data

2020-01-08 | OEX00002200 | NODE

AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)

Project description:Study purpose: to explore the entire spectrum of proteomic and genomic changes (amongst others) involved in diseases and in healthy/control populations. The Study is designed to discover biomarkers, develop and validate diagnostic assays, instruments and therapeutics as well as other medical research. Specifically, researchers may analyze proteins, RNA, DNA copy number changes, including large and small (1,000-100,000 kb) scale rearrangements, transcription profiles, epigenetic modifications, sequence variation, and sequence in both diseased tissue and case-matched germline DNA from Subjects.

| 62369 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data